



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: Landsman, Robert S.
)	
Kevin P. BAKER, et al.)	Art Unit: 1647
)	
Application Serial No. 10/015,395)	Confirmation No: 9919
)	
Filed: December 12, 2001)	Attorney's Docket No. 39780-2830 P1C57
)	
For: SECRETED AND)	Customer No. 35489
TRANSMEMBRANE)	
POLYPEPTIDES AND NUCLEIC)	
ACIDS ENCODING THE SAME)	

EXPRESS MAIL LABEL NO. EL 977 678 230 US
DATE MAILED: SEPTEMBER 9, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- | | | |
|--------------------------|-----|--|
| <input type="checkbox"/> | (1) | It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) |
| | | -- OR -- |
| <input type="checkbox"/> | (2) | It is being filed within 3 months of entry of a national stage |
| | | -- OR -- |
| <input type="checkbox"/> | (3) | It is being filed before the mail date of the first Office Action on the merits |
| | | -- OR -- |

☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; or

☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39780-2830 P1C57)**.

Respectfully submitted,

By: 

Anna L. Barry, Ph.D. (Reg. No. 51,436)

Dated: September 9, 2004

HELLER EHRMAN WHITE & MCAULIFFE LLP

275 Middlefield Road

Menlo Park, California 94025-3506

Telephone: (650) 324-7000

Facsimile: (650) 324-0638

INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO.: 39780-2830 P1C57			SERIAL NO.: 10/015,395	
			APPLICANT : Kevin P. BAKER, et al.				
			FILING DATE: 12/12/2001			GROUP: 1647	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Dayhoff, Accession No.: P_AAB50925, WO 200073452-A2, Pub Date: December 7, 2000, Ashkenazi, A.J., et al.						
	Dayhoff, Accession No.: P_AAB20119, WO 200105972-A1, Pub Date: January 25, 2001, Ashkenazi, A.J., et al.						
	Dayhoff, Accession No.: P_AAU12428, WO 200140466-A2, Pub Date: June 7, 2001, Baker, K.P., et al.						
	Dayhoff, Accession No.: P_AAM25855, WO 200153455-A2, Pub Date: July 26, 2001, Tang, Y.T., et al.						
	Dayhoff, Accession No.: P_AAY87294, WO 200000610-A2, Pub Date: January 6, 2000, Lal, P., et al.						
	Dayhoff, Accession No.: AAY99409, WO200012708-A2, Pub Date: March 9, 2000, Baker, K. et al.						
	Dayhoff, Accession No.: AAB33452, WO 200053758-A2, Pub Date: September 14, 2000, Ashkenazi, A.J., et al.						
	Dayhoff, Accession No.: P_AAB12160, WO 200029448-A2, Pub Date: May 25, 2000, Kato, S., et al.						
	Dayhoff, Accession No.: P_AAY19548, WO 9922243-A1, Pub Date: May 6, 1999, Feng, P., et al.						
	GenBank, Accession No.: P_AAC91484, WO 200073452-A2, Pub Date: December 7, 2000, Ashkenazi, A.J., et al.						
	GenBank, Accession No.: P_AAF30061, WO 200105972-A1, Pub Date: January 25, 2001, Ashkenazi, A.J., et al.						
	GenBank, Accession No.: P_AAS21500, WO 200140466-A2, Pub Date: June 7, 2001, Baker, K.P., et al.						
	GenBank, Accession No.: P_AAA37091, WO 200012708-A2, Pub Date: March 9, 2000, Baker, K., et al.						
	GenBank, Accession No.: P_AAC58617, WO 200053758-A2, Pub Date: September 14, 2000, Ashkenazi, A.J., et al.						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO.: 39780-2830 P1C57		SERIAL NO.: 10/015,395		
			APPLICANT : Kevin P. BAKER, et al.				
			FILING DATE: 12/12/2001		GROUP: 1647		
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	GenBank, Accession No.: AX055463, WO 0073452-A, Pub Date: December 7, 2000, Ashkenazi, A.J., et al.						
	GenBank, Accession No.: AX077035, WO 0105972-A, Pub Date: January 25, 2001, Ashkenazi, A.J., et al.						
	GenBank, Accession No.: P_AAZ98179, WO 200000610-A2, Pub Date: January 6, 2000, Lal, P., et al.						
	GenBank, Accession No.: P_AAH99796, WO 200153455-A2, Pub Date: July 26, 2001, Tang, Y.T., et al.						
	GenBank, Accession No.: P_AAX61428, WO 9922243-A1, Pub Date: May 6, 1999, Feng, P., et al.						
	GenBank, Accession No.: P_AAA62073, WO 200029448-A2, Pub Date: May 25, 2000, Kato, S., et al.						
	Fung-Leung, W. et al., "Tepoxalin, A Novel Immunomodulatory Compound Synergizes With CSA in Suppression of Graft-Versus-Host Reaction and Allogeneic Skin Graft Rejection", TRANSPLANTATION, Vol. 60, No. 4, pp. 362-368, August 27, 1995.						
	Rampart, M., et al., "Granulocyte Chemotactic Protein/Interleukin-8 Induces Plasma Leakage and Neutrophil Accumulation in Rabbit Skin", American Journal of Pathology, Vol. 135, No. 1, pp. 21-25, July 1989.						
	Schnabel, M., et al., "Osteoarthritis and Cartilage", Journal of the Osteoarthritis Research Society International, Vol. 10, pp. 62-70, 2002.						
	Shim, Jae-Hyuck, et al., "Immunosuppressive Effects of Tautomycin In Vivo and In Vivo via T Cell-Specific Apoptosis Induction", PNAS, Vol. 99, No. 16; pp 10617-10622, Aug. 6, 2002.						
	Zhang, Yaou, et al., "Versican Modulates Embryonic Chondrocyte Morphology via the Epidermal Growth Factor-like Motifs in G3", Experimental Cell Research, 263, pp. 33-42, 2001.						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.